Matches in SemOpenAlex for { <https://semopenalex.org/work/W2065832783> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2065832783 abstract "Background: Tumor immune cell infiltrates influence prognosis of node negative breast cancer (BC), and intratumoral B-cells and T-cells are of importance for achieving response to chemotherapy in triple negative BC. The role of tumor infiltrating macrophages remains unclear, but they might promote tumorigenesis. We investigated the prognostic value of CD68 mRNA levels within the luminal, HER2-positive and triple negative subtypes in the FinHer trial patient population, and evaluated their predictive value on survival outcomes achieved with adjuvant trastuzumab and chemotherapy in early breast cancer. Methods: RNA was extracted from formalin-fixed paraffin-embedded (FFPE) tumor tissue of 917 (90.8%) patients out of the 1010 patients who participated in the FinHer trial. Intratumoral macrophage infiltration was assessed by measuring breast tumor CD68 mRNA content using RT-qPCR from representative FFPE tissue samples. Breast cancer molecular subtypes (luminal, HER2 positive and triple-negative) were approximated using immunohistochemistry (IHC) and central CISH testing data obtained from the FinHer trial datafile. Prognostic significance of CD68 on distant disease-free survival (DDFS) was assessed using Kaplan-Meyer analysis and log-rank test. Results: Tumor CD68 mRNA expression was normally distributed with median expression of 33.56 (dCt). CD68 mRNA levels correlated weakly with estrogen receptor (ER) mRNA expression and ER protein levels (r = 0.11 and r = 0.15, respectively; p Conclusions: The study validates tumor CD68 concentration as a prognostic biomarker in HER2-positive early breast cancer. Patients with HER2-positive cancer and few tumor macrophages (low tumor CD68 mRNA content) benefitted from addition of trastuzumab to chemotherapy, whereas patients with HER2-positive BC with high tumor macrophage content derived no benefit from adjuvant trastuzumab. Trastuzumab may be effective only for macrophage-poor HER2-positive cancers that are prone to antibody-dependent cellular cytotoxicity (ADCC), whereas it may have little efficacy for cancers that progress despite or due to high intratumoral macrophage content that interferes with ADCC. Other agents, such as T-DM1, might work better than trastuzumab in the subset of women who have HER2-positive BC with a high tumor macrophage content. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-08-06." @default.
- W2065832783 created "2016-06-24" @default.
- W2065832783 creator A5006535775 @default.
- W2065832783 creator A5006874570 @default.
- W2065832783 creator A5014919760 @default.
- W2065832783 creator A5024937203 @default.
- W2065832783 creator A5035409107 @default.
- W2065832783 creator A5041690137 @default.
- W2065832783 creator A5068108014 @default.
- W2065832783 creator A5078556449 @default.
- W2065832783 creator A5087534912 @default.
- W2065832783 creator A5090418139 @default.
- W2065832783 creator A5090618504 @default.
- W2065832783 date "2013-12-15" @default.
- W2065832783 modified "2023-09-27" @default.
- W2065832783 title "Abstract P1-08-06: Low tumor CD68 mRNA content (intratumoral macrophages) is predictive for benefit from adjuvant trastuzumab in HER2-positive breast cancer: An analysis of the FinHER trial" @default.
- W2065832783 doi "https://doi.org/10.1158/0008-5472.sabcs13-p1-08-06" @default.
- W2065832783 hasPublicationYear "2013" @default.
- W2065832783 type Work @default.
- W2065832783 sameAs 2065832783 @default.
- W2065832783 citedByCount "0" @default.
- W2065832783 crossrefType "proceedings-article" @default.
- W2065832783 hasAuthorship W2065832783A5006535775 @default.
- W2065832783 hasAuthorship W2065832783A5006874570 @default.
- W2065832783 hasAuthorship W2065832783A5014919760 @default.
- W2065832783 hasAuthorship W2065832783A5024937203 @default.
- W2065832783 hasAuthorship W2065832783A5035409107 @default.
- W2065832783 hasAuthorship W2065832783A5041690137 @default.
- W2065832783 hasAuthorship W2065832783A5068108014 @default.
- W2065832783 hasAuthorship W2065832783A5078556449 @default.
- W2065832783 hasAuthorship W2065832783A5087534912 @default.
- W2065832783 hasAuthorship W2065832783A5090418139 @default.
- W2065832783 hasAuthorship W2065832783A5090618504 @default.
- W2065832783 hasConcept C121608353 @default.
- W2065832783 hasConcept C126322002 @default.
- W2065832783 hasConcept C142724271 @default.
- W2065832783 hasConcept C143998085 @default.
- W2065832783 hasConcept C204232928 @default.
- W2065832783 hasConcept C2776460901 @default.
- W2065832783 hasConcept C2779786085 @default.
- W2065832783 hasConcept C2780110267 @default.
- W2065832783 hasConcept C2908647359 @default.
- W2065832783 hasConcept C502942594 @default.
- W2065832783 hasConcept C530470458 @default.
- W2065832783 hasConcept C555283112 @default.
- W2065832783 hasConcept C71924100 @default.
- W2065832783 hasConcept C99454951 @default.
- W2065832783 hasConceptScore W2065832783C121608353 @default.
- W2065832783 hasConceptScore W2065832783C126322002 @default.
- W2065832783 hasConceptScore W2065832783C142724271 @default.
- W2065832783 hasConceptScore W2065832783C143998085 @default.
- W2065832783 hasConceptScore W2065832783C204232928 @default.
- W2065832783 hasConceptScore W2065832783C2776460901 @default.
- W2065832783 hasConceptScore W2065832783C2779786085 @default.
- W2065832783 hasConceptScore W2065832783C2780110267 @default.
- W2065832783 hasConceptScore W2065832783C2908647359 @default.
- W2065832783 hasConceptScore W2065832783C502942594 @default.
- W2065832783 hasConceptScore W2065832783C530470458 @default.
- W2065832783 hasConceptScore W2065832783C555283112 @default.
- W2065832783 hasConceptScore W2065832783C71924100 @default.
- W2065832783 hasConceptScore W2065832783C99454951 @default.
- W2065832783 hasLocation W20658327831 @default.
- W2065832783 hasOpenAccess W2065832783 @default.
- W2065832783 hasPrimaryLocation W20658327831 @default.
- W2065832783 hasRelatedWork W1553911486 @default.
- W2065832783 hasRelatedWork W1966014735 @default.
- W2065832783 hasRelatedWork W1970542820 @default.
- W2065832783 hasRelatedWork W1994238092 @default.
- W2065832783 hasRelatedWork W2008102732 @default.
- W2065832783 hasRelatedWork W2036539825 @default.
- W2065832783 hasRelatedWork W2057789711 @default.
- W2065832783 hasRelatedWork W2084732276 @default.
- W2065832783 hasRelatedWork W2158627893 @default.
- W2065832783 hasRelatedWork W2320044125 @default.
- W2065832783 hasRelatedWork W2369913636 @default.
- W2065832783 hasRelatedWork W2613614174 @default.
- W2065832783 hasRelatedWork W2621167521 @default.
- W2065832783 hasRelatedWork W2790356395 @default.
- W2065832783 hasRelatedWork W2791150505 @default.
- W2065832783 hasRelatedWork W2801132258 @default.
- W2065832783 hasRelatedWork W2806911036 @default.
- W2065832783 hasRelatedWork W2894490178 @default.
- W2065832783 hasRelatedWork W2922610753 @default.
- W2065832783 hasRelatedWork W2972550474 @default.
- W2065832783 isParatext "false" @default.
- W2065832783 isRetracted "false" @default.
- W2065832783 magId "2065832783" @default.
- W2065832783 workType "article" @default.